These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 36146723)

  • 41. Immune response to COVID-19 vaccination in a population with and without a previous SARS-CoV-2 infection.
    Duro M; Almeida C; Duro I; Sarmento A
    Ir J Med Sci; 2023 Apr; 192(2):731-739. PubMed ID: 35676470
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study.
    Cerna K; Duricova D; Lukas M; Machkova N; Hruba V; Mitrova K; Kubickova K; Kostrejova M; Teplan V; Vasatko M; Kastylova K; Lukas M
    Inflamm Bowel Dis; 2022 Oct; 28(10):1506-1512. PubMed ID: 34849919
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Assessing the long-stand antibody response induced by COVID-19 vaccines: A study in an educational cohort in San Luis, Argentina.
    Eliçabe RJ; Distel MN; Jofré BL; Leporati M; Silva JE; Arias JL; Gorlino CV; Funes SC; Velazquez M; Vitale P; Davicino RC; Di Genaro MS
    Vaccine; 2023 Jan; 41(2):476-485. PubMed ID: 36481109
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.
    Jarius S; Bieber N; Haas J; Wildemann B
    J Neurol; 2022 Oct; 269(10):5198-5212. PubMed ID: 35737110
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of three different COVID-19 vaccine platforms (CoronaVac, BTN162b2, and Ad5-nCoV) in individuals with and without prior COVID-19: Reactogenicity and neutralizing antibodies.
    Morales-Núñez JJ; Muñoz-Valle JF; Machado-Sulbarán AC; Díaz-Pérez SA; Torres-Hernández PC; Panduro-Espinoza BV; Gallegos-Díaz de Leon JA; Munguía-Ramirez CD; Hernández-Bello J
    Immunol Lett; 2022 Dec; 251-252():20-28. PubMed ID: 36279685
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of Waning Neutralizing Antibody Responses Against the Omicron Variant 6 Months After Natural Severe Acute Respiratory Syndrome Coronavirus 2 Infection (With or Without Subsequent Coronavirus Disease 2019 [COVID-19] Vaccination) Versus 2-Dose COVID-19 Vaccination.
    Lim SY; Park S; Kim JY; Kim S; Jee Y; Kim SH
    Clin Infect Dis; 2022 Dec; 75(12):2243-2246. PubMed ID: 35686300
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity.
    Rodda LB; Morawski PA; Pruner KB; Fahning ML; Howard CA; Franko N; Logue J; Eggenberger J; Stokes C; Golez I; Hale M; Gale M; Chu HY; Campbell DJ; Pepper M
    Cell; 2022 Apr; 185(9):1588-1601.e14. PubMed ID: 35413241
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cellular and Humoral Immune Responses to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease Patients.
    Cerna K; Duricova D; Hindos M; Hindos Hrebackova J; Lukas M; Machkova N; Hruba V; Mitrova K; Kubickova K; Kastylova K; Teplan V; Lukas M
    J Crohns Colitis; 2022 Sep; 16(9):1347-1353. PubMed ID: 35358307
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens.
    Klemis V; Schmidt T; Schub D; Mihm J; Marx S; Abu-Omar A; Ziegler L; Hielscher F; Guckelmus C; Urschel R; Wagenpfeil S; Schneitler S; Becker SL; Gärtner BC; Sester U; Sester M
    Nat Commun; 2022 Aug; 13(1):4710. PubMed ID: 35953492
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Preservation of Anti-SARS-CoV-2 Neutralizing Antibodies in Breast Milk: Impact of Maternal COVID-19 Vaccination and Infection.
    Suteerojntrakool O; Mekangkul E; Maitreechit D; Khabuan S; Sodsai P; Hirankarn N; Thumbovorn R; Chomtho S
    Breastfeed Med; 2024 May; 19(5):340-348. PubMed ID: 38506333
    [No Abstract]   [Full Text] [Related]  

  • 51. Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination.
    Motsoeneng BM; Manamela NP; Kaldine H; Kgagudi P; Hermanus T; Ayres F; Makhado Z; Moyo-Gwete T; van der Mescht MA; Abdullah F; Boswell MT; Ueckermann V; Rossouw TM; Madhi SA; Moore PL; Richardson SI
    Front Immunol; 2023; 14():1231276. PubMed ID: 37600825
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of Prior Infection on SARS-CoV-2 Antibody Responses in Vaccinated Long-Term Care Facility Staff.
    Gallichotte EN; Nehring M; Stromberg S; Young MC; Snell A; Daniels J; Pabilonia KL; VandeWoude S; Ehrhart N; Ebel GD
    mSphere; 2022 Aug; 7(4):e0016922. PubMed ID: 35862798
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of SARS-CoV-2 Humoral Response Following Vaccination with ChAdOx1 nCoV-19 (Covishield™) and/or Sinopharm, BBIBP-CorV (Vero cell™).
    Kamar SB; Pandey H; Shahi R; Puri S; Yadav GK; Amgain K
    J Nepal Health Res Counc; 2024 Mar; 21(3):523-529. PubMed ID: 38615227
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A potential association between obesity and reduced effectiveness of COVID-19 vaccine-induced neutralizing humoral immunity.
    Faizo AA; Qashqari FS; El-Kafrawy SA; Barasheed O; Almashjary MN; Alfelali M; Bawazir AA; Albarakati BM; Khayyat SA; Hassan AM; Alandijany TA; Azhar EI
    J Med Virol; 2023 Jan; 95(1):e28130. PubMed ID: 36068377
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunogenicity and efficacy of          heterologous ChAdOx1-BNT162b2 vaccination.
    Pozzetto B; Legros V; Djebali S; Barateau V; Guibert N; Villard M; Peyrot L; Allatif O; Fassier JB; Massardier-Pilonchéry A; Brengel-Pesce K; Yaugel-Novoa M; Denolly S; Boson B; Bourlet T; Bal A; Valette M; Andrieu T; Lina B; ; Cosset FL; Paul S; Defrance T; Marvel J; Walzer T; Trouillet-Assant S
    Nature; 2021 Dec; 600(7890):701-706. PubMed ID: 34673755
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Humoral and cellular immunity of two-dose inactivated COVID-19 vaccination in Chinese children: A prospective cohort study.
    Wang H; Gan M; Wu B; Zeng R; Wang Z; Xu J; Li J; Zhang Y; Cao J; Chen L; Di D; Peng S; Lei J; Zhao Y; Song X; Yuan T; Zhou T; Liu Q; Yi J; Wang X; Cai H; Lei Y; Wen Y; Li W; Chen Q; Wang Y; Long P; Yuan Y; Wang C; Pan A; Wang Q; Gong R; Fan X; Wu T; Liu L
    J Med Virol; 2023 Jan; 95(1):e28380. PubMed ID: 36478357
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Humoral and adaptive immune responses to the SARS-CoV-2 vaccine.
    Rizzo R; Bortolotti D; Morandi L; Rizzo S; Schiuma G; Beltrami S; Papi A; Contoli M
    Int J Infect Dis; 2022 Sep; 122():412-414. PubMed ID: 35750264
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hybrid immunity expands the functional humoral footprint of both mRNA and vector-based SARS-CoV-2 vaccines.
    Kaplonek P; Deng Y; Shih-Lu Lee J; Zar HJ; Zavadska D; Johnson M; Lauffenburger DA; Goldblatt D; Alter G
    Cell Rep Med; 2023 May; 4(5):101048. PubMed ID: 37182520
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of humoral and cellular immune responses between ChAd-BNT heterologous vaccination and BNT-BNT homologous vaccination following the third BNT dose: A prospective cohort study.
    Sim W; Kang H; Jung J; Lee J; Ko GY; Park HS; Choi J; Park K; Oh EJ
    Front Immunol; 2023; 14():1120556. PubMed ID: 36936965
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Innate Immune Responses of Vaccinees Determine Early Neutralizing Antibody Production After ChAdOx1nCoV-19 Vaccination.
    Shen CF; Yen CL; Fu YC; Cheng CM; Shen TC; Chang PD; Cheng KH; Liu CC; Chang YT; Chen PL; Ko WC; Shieh CC
    Front Immunol; 2022; 13():807454. PubMed ID: 35145520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.